Icon Advisers Inc Eli Lilly & CO Transaction History

Icon Advisers Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 05, 2020	SELL	$146.22 - $169.13 $4.62 Million - $5.34 Million	-31,600 Closed	0 $0
Q4 2019 Jan 31, 2020	SELL	$106.92 - $132.43 $160,380 - $198,645	-1,500 Reduced 4.53%	31,600 $4.15 Million
Q4 2018 Feb 04, 2019	SELL	$105.9 - $118.64 $953,100 - $1.07 Million	-9,000 Reduced 21.38%	33,100 $3.83 Million
Q3 2018 Nov 05, 2018	BUY	$85.86 - $107.31 $472,230 - $590,205	5,500 Added 15.03%	42,100 $4.52 Million
Q4 2017 Feb 06, 2018	SELL	$81.94 - $87.89 $2.56 Million - $2.74 Million	-31,200 Reduced 46.02%	36,600 $3.09 Million
Q3 2017 Nov 08, 2017	BUY	$77.07 - $85.54 $5.23 Million - $5.8 Million	67,800	67,800 $5.8 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Icon Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Icon Advisers Inc with notifications on news.